– CANADA, Montreal – Repare Therapeutics Inc. (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Dr. Steve Stein (M.D.) to its Board of Directors, effective at AGM in June 2024.
The Company also announced that Todd Foley will not stand for re-election to the Board at the AGM on June 17, 2024.
“We are also honored to welcome Dr. Stein to our Board. His deep experience, proven track record and accomplishments in oncology clinical drug development will provide valuable guidance as Repare’s pipeline advances to later stages of development,” said CEO, Lloyd Segal.
About Dr. Steven H. Stein
Dr. Steve Stein serves as CMO of Incyte Corporation, a position he has held since March 2015. At Incyte, he leads all medical and scientific activities involving clinical development, clinical operations, pharmacovigilance, clinical pharmacology, scientific communications, and medical affairs. Before joining Incyte, from May 2011 to February 2015, Dr. Steve Stein served as SVP and Head of U.S. Clinical Development and Medical Affairs at Novartis Oncology. Before then, he was employed by GlaxoSmithKline from February 2004 to April 2011, serving first as its Head of Medicines Development for Hematology and Supportive Care and then as VP of global Oncology and Clinical Development. Dr. Stein also previously served on the board of directors of Kura Oncology, Inc. from 2017 until May 2023.
“I am honored to join the Board of Directors at Repare at such a critical time in the Company’s growth and evolution, and am looking forward to working with its leadership team to deliver on the Company’s mission to develop synthetic lethal medicines that meaningfully improve the lives of cancer patients,” said Dr. Steve Stein.
Dr. Steve Stein earned his MBBCH from the University of Witwatersrand in Johannesburg, South Africa. He has authored more than 100 scientific papers and presentations and is an Adjunct Assistant Professor in the School of Medicine, University of Pennsylvania. Dr. Stein is also an active member of several professional and scientific societies and academic committees.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes lunresertib, a PKMYT1 inhibitor currently in Phase 1/2 clinical development; camonsertib, a potential leading ATR inhibitor currently in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical Polθ ATPase inhibitor program; as well as additional, undisclosed preclinical programs.
SOURCE: https://www.reparerx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
